Name | 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide |
---|---|
Synonyms |
GNF-Pf-192
Benzamil 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid benzylcarbamimidoyl-amide |
Description | Benzamil (Benzylamiloride), an Amiloride analogue, is a Na+/Ca2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil inhibits TRPP3-mediated Ca2+-activated currents, with an IC50 of 1.1 μM[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Benzamil (Benzylamiloride) inhibits neuronal and heterologously expressed small conductance Ca2+-activated K2+ channels[4]. |
In Vivo | Benzamil (Benzylamiloride) (0.7 mg/kg/day; s.c.) treated stroke-prone spontaneously hypertensive rats (SHRSP) survived, on average, until 16.1 weeks of age in SHRSP rats[5]. |
References |
Molecular Formula | C13H14ClN7O |
---|---|
Molecular Weight | 356.21100 |
Exact Mass | 355.07200 |
PSA | 145.30000 |
LogP | 3.59470 |
Storage condition | 2-8°C |
~73% 2898-76-2 |
Literature: BOEHRINGER INGELHEIM INTERNATIONAL GMBH; KLEY, Joerg; HAERLE, Daniel; LINZ, Guenter; STEHLE, Sandra Patent: WO2013/64451 A1, 2013 ; Location in patent: Page/Page column 37; 38 ; |
~% 2898-76-2 |
Literature: BOEHRINGER INGELHEIM INTERNATIONAL GMBH; KLEY, Joerg; HAERLE, Daniel; LINZ, Guenter; STEHLE, Sandra Patent: WO2013/64451 A1, 2013 ; |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |